Sustained Benefit in Patients with Relapsed/Refractory Mantle Cell Lymphoma Demonstrated by 3 ½-Year Follow-Up Data of IMBRUVICA® (ibrutinib)

Source: Johnson and Johnson - Category: Pharmaceuticals Source Type: news